Technology

5 things we didn’t put on our 2024 list of 10 Breakthrough Technologies

December 8, 2023
No one can predict the future, but  here at MIT Technology Review we spend much of our time thinking about what it might hold. One thing we know is that it’s especially hard to make predictions about technology. Most emerging technologies fizzle or flame out. Some start out as consumer devices but wind up finding…

The Download: inside the first CRISPR treatment, and smarter robots

December 8, 2023
This is today’s edition of The Download, our weekday newsletter that provides a daily dose of what’s going on in the world of technology. The lucky break behind the first CRISPR treatment The world’s first commercial gene-editing treatment is set to start changing the lives of people with sickle-cell disease. It’s called Casgevy, and it was approved…

Medical microrobots that can travel inside your body are (still) on their way

December 8, 2023
This article first appeared in The Checkup, MIT Technology Review’s weekly biotech newsletter. To receive it in your inbox every Thursday, and read articles like this first, sign up here. The human body is a labyrinth of vessels and tubing, full of barriers that are difficult to break through. That poses a serious hurdle for doctors.…

Startups must master operations

December 7, 2023

Josh Claman Contributor Share on X Josh Claman is the CEO of Accelsius, makers of direct-to-chip, two-phase cooling technology. An advocate for the power of transformative technology throughout his 30-year career, Mr. Claman has grown and repositioned businesses at Dell, NCR and AT&T. Most of the world’s top-valued private companies are software companies. That’s not surprising — innovations in AI, social […]

© 2023 TechCrunch. All rights reserved. For personal use only.

The lucky break behind the first CRISPR treatment

December 7, 2023
The world’s first commercial gene-editing treatment is set to start changing the lives of people with sickle-cell disease. It’s called Casgevy, and it was approved last month in the UK. US approval is pending this week.  The treatment, which will be sold in the US by Vertex Pharmaceuticals, employs CRISPR, the Nobel-winning molecular scissors that have…

The Download: Google’s Gemini is here, and Sundar Pichai talks AI

December 7, 2023
This is today’s edition of The Download, our weekday newsletter that provides a daily dose of what’s going on in the world of technology. Google DeepMind’s new Gemini model looks amazing—but could signal peak AI hype Hype about Gemini, Google DeepMind’s long-rumored response to OpenAI’s GPT-4, has been building for months. Now, the company has finally revealed…

How carbon removal technology is like a time machine

December 7, 2023
This article is from The Spark, MIT Technology Review’s weekly climate newsletter. To receive it in your inbox every Wednesday, sign up here. If you could go back in time, what would you change about your life, or the world? The idea of giving myself some much-needed advice is appealing (don’t cut your own bangs…

Google CEO Sundar Pichai on Gemini and the coming age of AI

December 6, 2023
Google released the first phase of its next-generation AI model, Gemini, today. Gemini reflects years of efforts from inside Google, overseen and driven by its CEO Sundar Pichai. (You can read all about Gemini in our report from Melissa Heikkila and Will Douglas Heaven here.)  Pichai, who previously oversaw Chrome and Android, is famously product-obsessed.…

Google DeepMind’s new Gemini model looks amazing—but could signal peak AI hype

December 6, 2023
Hype about Gemini, Google DeepMind’s long-rumored response to OpenAI’s GPT-4, has been building for months. Today the company finally revealed what it has been working on in secret all this time. Was the hype justified? Yes—and no.  Gemini is Google’s biggest AI launch yet, its push to take on competitors OpenAI and Microsoft in the…